DSIP reconstitution calculator
Type in a vial size, the diluent volume you added, and a dose figure — the calculator below converts those three numbers into a concentration, a draw volume, and a syringe reading. It performs the same arithmetic as our tirzepatide and sermorelin calculators. What it cannot do, for DSIP specifically, is check that arithmetic against an FDA-approved product's own label, because no such label — or product — exists. Read why below before you use it.
There is no approved product or dosing standard behind this calculator
DSIP — "delta sleep-inducing peptide" — is a nine-amino-acid neuropeptide first described in animal sleep research in the 1970s. "Emideltide" is the formal name FDA's own nomination and committee materials use for the same molecule; the two names are not two different compounds. Its published research base covers sleep, opioid and alcohol withdrawal, stress, and pain modulation — mostly preclinical and dated work, not the kind of human dosing evidence a label is built from. It has never had an FDA-approved drug product: a direct check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for both "DSIP" and "emideltide."
Its compounding status has also moved recently, and landed somewhere less favorable than most of the other peptides on this calculator: DSIP sat on FDA's interim Section 503A Category 2 list (bulk substances presenting significant safety risks that pharmacies should not compound) from 2023 until April 15, 2026, when FDA removed it — along with eleven other peptides, including BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax — because the nomination behind that listing was withdrawn, effective April 22, 2026. That removal does not make compounding DSIP legal; it only lifts the "significant safety risk" flag. The further review that followed has already happened, and it did not go DSIP's way: at FDA's Pharmacy Compounding Advisory Committee meeting on July 24, 2026, the committee voted 6-7-1 on whether to recommend adding DSIP to the 503A bulks list for its nominated opioid-withdrawal, chronic-insomnia and narcolepsy uses — and the vote failed. DSIP was the only one of the seven peptides reviewed that week that did not get a majority recommendation. Unlike BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, which are now recommended and simply awaiting final FDA rulemaking, DSIP currently has no committee recommendation behind it at all.
What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a particular vial is what its label claims, that the dose you enter is appropriate for you, that it is currently legal for a pharmacy to have compounded it, or that the product you drew that number from came from a legitimate source. A correct-looking syringe reading is not evidence that any of those things are true.
Sources: DailyMed structured-product-label search for "DSIP" and "emideltide" (zero results for both), FDA's April 15, 2026 removal of DSIP/Emideltide from the interim Section 503A Category 2 bulk drug substances list, and reporting on FDA's July 24, 2026 Pharmacy Compounding Advisory Committee vote on DSIP/Emideltide, all independently checked 2026-08-02. View the DailyMed search for "DSIP" or for "emideltide".
Where to go next
- Compare against the compounds this calculator supports that do have an FDA-approved reference product, on the calculator hub.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.